Zachary Bessette

GU Oncology Now

An analysis presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium highlighted real-world treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who received at least 1 line of therapy in a community oncology practice.Results showed treatment patterns that diverge from current guideline recommendations.Traditionally, androgen deprivation therapy (ADT) has been a standard-of-care treatment for mHSPC. However, early use of docetaxel and novel androgen receptor inhibitors (nARIs) has demonstrated improved clinical outcomes.<a href="https://meetings.asco.org/abstracts-presentations/217590" target="_blank" rel="noopener">Sreevalsa Appukkuttan, MBBS, MPH, and colleagues</a> designed a retrospective, observational study of health records from 5 Cancer Treatment Centers of America sites to assess real-world treatment of mHSPC in the community setting. A total of 523 patients who were treated with ADT, docetaxel, or nARIs for at least 6 months from January 2015 to March 2021 were included in the analysis.Researchers observed treatment patterns from first line of therapy to metastatic castration resistance, death, or lost-to-follow-up until March 2022. Line of therapy was defined as first to last date of active drug therapy, excluding long-term hormone agonists. First line of therapy was defined as initial regimen with no new drugs after at least 30 days from the start date.After a median follow-up time of 2.9 years, researchers found the most common first line of therapy regimen was either ADT alone or ADT with first-generation ARIs. Forty-six percent of patients received a second line of therapy, and 15% received a third line of therapy. Mean duration of first and second active lines of therapy were 12 and 10 months, respectively.Researchers noted that among the 65% and 78% patients who discontinued first- and second-line therapy, respectively, the majority discontinued due to progression of disease (35% and 53%, respectively).&ldquo;Despite recommendations from guidelines on early intensification of therapy in mHSPC, [we found] that most patients received either ADT alone or ADT plus first-generation ARI [as first-line therapy regimens],&rdquo; they concluded. &ldquo;Further studies are needed to assess the factors associated with nonintensification of treatments.&rdquo;

Assessing Utilization Patterns of mHSPC Treatment in a Community Oncology Practice Setting

American Society of Clinical Oncology Genitourinary Cancers Symposium 2023

ASCO GU Symposium 2023

An analysis highlighted real-world treatment of patients with mHSPC who received at least 1 line of therapy in a community oncology practice.

Utilization Patterns of mHSPC Treatment in the Community

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe